Your prediction
Pros and Cons of M1 Ltd. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of M1 Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| M1 Ltd. | - | - | - | - | - | - | - |
| Spok Holdings Inc. | -0.520% | 1.075% | 3.867% | -35.395% | -14.390% | -27.132% | 27.891% |
| SmarTone Telecommunications Holdings Ltd | - | 0.943% | 5.941% | 5.941% | 8.300% | -4.464% | 18.363% |
| Apt Satellite Hldgs | 0.000% | 0.000% | 0.529% | -5.941% | -24.000% | -24.000% | -18.803% |
News
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
Key Points
- Interested in Contineum Therapeutics, Inc.? Here are five stocks we like better.
- Contineum remains focused on PIPE-791 for idiopathic pulmonary fibrosis (IPF), saying the drug’s
IRSA Inversiones Y Representaciones Q3 Earnings Call Highlights
IRSA Inversiones Y Representaciones (NYSE:IRS) reported a sharply higher net result for the first nine months of fiscal 2026, supported by stronger performance across its rental businesses and